International Edition
Latest News
Health

Maryland Approves First-in-the-Nation Payment Limits on High-Cost Diabetes Drugs Jardiance and Ozempic

“This landmark move will save state and local government millions of dollars,” Vincent DeMarco, president of the Maryland Healthcare for All coalition, said during public comments ahead of the board votes Monday. State health officials voted on Monday…

Maryland Approves First-in-the-Nation Payment Limits on High-Cost Diabetes Drugs Jardiance and Ozempic

“This landmark move will save state and local government millions of dollars,” Vincent DeMarco, president of the Maryland Healthcare for All coalition, said during public comments ahead of the board votes Monday.

State health officials voted on Monday to set upper payment limits on Jardiance and Ozempic for government plans, WYPR reported. The Maryland Prescription Drug Affordability Board unanimously decided for the first time to cap state spending on high-cost medications.

Board staff estimate that limiting reimbursement rates for the two Type 2 diabetes medications will save state and local government healthcare plans roughly $6.1 million. The regulations are scheduled to take effect on Jan. 1, 2027. “Now, the state is saying, you could charge whatever you want, but we are only going to pay a reasonable amount here in Maryland.”

Pharmaceutical manufacturers and patient advocacy groups caution that upper payment limits could restrict patient access and alter pharmacy formularies. Organizations such as the Aimed Alliance warned the board that reimbursement changes might trigger tighter utilization management.

Other industry representatives note that the projected $6.1 million in savings will flow directly to government health plans rather than lowering out-of-pocket costs at the pharmacy counter. Flat copays mean most participating members already receive standard coverage without direct savings from the caps. Board executive director Andrew York said that participating plans will receive supplemental rebates if net spending exceeds the established limits.

“These policies can introduce new incentives for insurers and pharmacy benefit managers (PBMs) that may ultimately restrict access to needed treatments through greater utilization management, formulary reshuffling, or adverse tiering,” according to a written comment to the board by the EACH/PIC coalition, a group of almost two dozen patient-advocacy groups for specific conditions.

Maryland Approves First-in-the-Nation Payment Limits on High-Cost Diabetes Drugs Jardiance and Ozempic
Photo: marylandmatters.org

“State and local governments have really been gouged by the high price of these drugs, and it made it harder for them to provide them and cover their employees with these drugs for all their uses,” DeMarco said.

If the regulations take effect without major disruptions, the board gains authority to apply limits to the private insurance market in 2028. An analysis commissioned by Maryland Health Care for All projects that expanding limits to private plans could increase annual savings to over $150 million annually. State leaders, including Gov. Wes Moore, have expressed support for aligning state limits with federal maximum fair prices established by Medicare.

Colorado enacted a similar payment limit on the autoimmune drug Enbrel in October 2025, though implementation remains stalled due to pending federal litigation filed by the manufacturer. Maryland officials maintain that the board retains authority to alter its policy if patient access suffers under the new limits.

This photograph taken on March 17, 2026, shows obesity doctor and consultant Swati Pradhan explaining the Ozempic GLP-1
Photo: thederrick.com

The upper payment limits apply specifically to Jardiance, used for diabetes and heart disease, and Ozempic, a treatment for Type 2 diabetes. Other formulations containing similar active ingredients, such as Wegovy, are not included in these current regulations.

The projected savings flow directly to participating state and local government health plans rather than reducing immediate out-of-pocket costs at the pharmacy counter. Participating plans will receive supplemental rebates if their net spending surpasses the state-set limits.

The regulations are set to take effect on Jan. 1, 2027, for eligible state and local government entities. Participation is voluntary during the first year and becomes mandatory for participating entities opting in by Jan. 1, 2028.

About the author: Health Desk

Health Desk at Archynewsy.